Treatment using blockers of TNF-α has been found to increase the number of platelets in refractory ITP patients, indicating that TNF-α may be an important participant in the pathogenesis of ITP [23]. The gene discussed is TNF; the disease is autoimmune thrombocytopenic purpura.